ArticleTranslational andrology and urology2026
MAGI3 inhibits renal clear cell carcinoma progression through the JAK-STAT3 pathway.
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clear cell renal cell carcinoma (ccRCC) is the most common kidney cancer subtype. While localized disease is treated surgically, therapeutic options for advanced cases remain limited. This highlights an urgent need for reliable prognostic markers and novel therapeutic targets. Therefore, this study aimed to clarify the clinical significance and functional role of MAGI3 in ccRCC. Methods: We analyzed MAGI3 expression in ccRCC and normal tissues using public datasets and clinical samples. Its correlation with clinicopathological features and patient survival was evaluated. The biological role of MAGI3 and its underlying mechanism were investigated through in vitro and Results: MAGI3 expression was significantly downregulated in tumor tissues compared with adjacent normal kidney specimens. Lower MAGI3 levels correlated positively with advanced tumor stage, higher Fuhrman nuclear grade, lymph node metastasis, increased infiltration of immunosuppressive cell populations, and poorer overall patient prognosis. Functional experiments further demonstrated that MAGI3 overexpression effectively suppressed ccRCC cell proliferation, migration, and invasion in vitro and in vivo by inhibiting STAT3 signaling phosphorylation and downstream transcriptional activity. Conclusions: Our study identifies MAGI3 as a novel tumor suppressor in ccRCC that constrains cancer progression via the STAT3 pathway. These results firmly establish MAGI3 as a potential prognostic biomarker for ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.